This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
Questions about our CME?
Questions about our CME?

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Effective Disease-Modifying Therapy for Allergic Rhinitis: Improving Patient Outcomes Through Allergen-specific Immunotherapy

Effective Disease-Modifying Therapy for Allergic Rhinitis: Improving Patient Outcomes Through Allergen-specific Immunotherapy

Format

Patient Case Study

Time to Complete

1 hour

Released

April 27, 2017

Expires

April 27, 2018
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Jointly provided by Global Education Group and Consultants in Medical Education (CiME)

Commercial Supporter

This activity is supported by an independent educational grant from Stallergenes Greer.

Program Description

Allergic rhinitis (AR) affects an estimated 1 in 6 Americans, a significant proportion of whom are sensitized against at least one of the five major grass species in the US. Patients with grass-pollen induced AR face a lifelong journey of seasonal symptom control without effective disease modification. Increasing understanding of the process of developing tolerance to specific grass pollen aeroallergens has resulted in the development of allergen immunotherapies that have the potential to alter disease course and provide significantly improved quality of life for patients with AR. This patient case activity will guide clinicians through the process of clinical history-taking, specific allergen testing, and discuss management plans that use complete patient sensitization profiles to direct both symptomatic control and disease modification of AR. This activity aims to increase learner competence at differentially diagnosing AR, designing effective symptom control plans, and working with patients to implement long-term disease modification via different allergen immunotherapy approaches.

Intended Audience

The educational design of this activity addresses the needs of allergists, otolaryngologists, immunologists and other health care professionals involved in the treatment of patients with grass-pollen induced allergic rhinitis

Educational Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Conduct a complete patient interview and exam to establish history, triggers, lung health and a clinical diagnosis of allergic rhinitis
  • Perform allergy testing to establish a definitive trigger in patients with a clinical diagnosis of allergic rhinitis
  • Discuss evidence-based treatment approaches for patients who are mono- or polysensitized versus allergic to grasses and other allergens
  • Compare subcutaneous versus sublingual immunotherapy in terms of efficacy, safety, rates of systemic reactions and a patient’s ability to adhere to the treatment course

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty

Deborah A. Gentile, MD
Adjunct Professor of Medicine; Drexel University School of Medicine
Director of Allergy/Asthma Research; Division of Pulmonary, Allergy and Critical Care Medicine; Allegheny Health Network
Pittsburgh, PA

Dr. Gentile reported a financial relationship with Stallergenes Greer.

Peter Socrates Creticos, MD
Associate Professor of Medicine, Johns Hopkins School of Medicine – Division of Allergy & Clinical Immunology
Director of Clinical Research, Creticos Research Group, LLC
Baltimore, MD

Dr. Creticos reported financial relationships with Stallergenes Greer, Circassia, Allakos, Inc., Anergis SA, Merck & Co., Inc., and WebMD LLC (Medscape).

Ayesha N. Khalid, MD, MBA
Cambridge Health Alliance; Clinical Instructor, Harvard Medical School
Concord, MA

Dr. Khalid reported financial relationships with 480 Biomedical, Castle Creek Pharma, Stallergenes Greer, Patient Doctor Technologies, Inc. (Doctella), Abbott, Lungpacer Medical Inc.

Accredited Provider Disclosure

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashely Marostica, RN, MSN, has nothing to disclose to report in regards to financial relationships.
Andrea Funk has nothing to disclose to report in regards to financial relationships.
Laura Gilsdorf has nothing to disclose to report in regards to financial relationships.
Chris Blagden, PhD, has nothing to disclose to report in regards to financial relationships.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and CiME. Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CiME do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

There is no fee for this activity. In order to receive credit, users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test. Participants will have 2 tries to achieve a passing score of 80% or higher.
  • Complete the activity evaluation.
Upon successful completion of this program, a statement of credit will be available to print from your CME History on myCME (located under My Account), which can be accessed at any time.

For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com.

If you have any other questions relating to your certificate or other issues with the activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

Global protects the privacy of personal and other information regarding participants, educational partners and joint sponsors. Global and our joint sponsors will not release personally identifiable information to a third party without the customer's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

RealCME privacy policy

myCME privacy policy
Add to Queue